04.29.25 -- The Cell And Gene Therapy Dilemma: Centralized Vs. Decentralized Manufacturing

Discover a cell line that enhances rAAV production by reducing host cell DNA encapsidation, improving safety and efficiency through genetic modifications that inhibit apoptotic DNA fragmentation.

Empty capsids in AAV preparations can reduce efficacy and trigger unwanted immune responses. Droplet Digital PCR offers a fast, precise, and easy way to quantify empty and full capsids in AAV samples.

Explore study results demonstrating the ability of Sartoclear depth filters to deliver high performance for AAV clarification, ensuring scalability, high recovery rates, and robust filtration.

Learn about a family of centrifuges and review of data collected on the centrifuges' performance for the harvest of cells in cell therapy production.

Cell and gene therapies are gaining traction in the biopharmaceutical world, but challenges will inevitably follow. Considerations for aseptic fill/finish are essential as this technology grows.

Here we explore the use of viral vectors in gene therapies, as well as factors that negatively affect them during manufacturing.

Watch as speakers share a variety of challenges encountered when closing and automating ancillary processes, and how closed automated platforms improved scalability and reproducibility.

This article discusses options for cell therapy process development and validation that minimize risks through quality control (QC), optimization, scaling, closing, automation, and assay development.

From personalized treatments to large-scale viral vector production, the future of ATMPs hinges on optimized automation. Delve into the technologies driving this transformation and the challenges ahead.

Cytotoxic compounding poses risks like contamination and exposure, causing serious health effects. Safety measures include isolators, PPE, SOPs, and advanced technologies like the Bioquell Qube.